Clinical Trial News and Research

RSS

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Starting rehabilitation sooner following knee arthroplasty surgery could pay dividends - for both patients and hospitals. Commencing physical therapy within 24 hours of surgery can improve pain, range of joint motion and muscle strength as well as cut hospital stays, according to new research in the journal Clinical Rehabilitation, published by SAGE.

6 Mar 2011

Scientists identify regulatory T cells responsible for limiting immune response

Scientists from the Walter and Eliza Hall Institute have identified the key immune cell population responsible for regulating the body's immune response.

6 Mar 2011

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Mar 2011

FDA approves change to prescribing information for Gilead Sciences' Letairis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.

5 Mar 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Medifocus Inc. is pleased to announce that two clinical presentations of the Company's breast cancer treatment system, the Microfocus APA-1000, will be made at the 21st Annual National Interdisciplinary Breast Center Conference , March 12-16, 2011 in Las Vegas , NV.

5 Mar 2011

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Liquidia Technologies today announced the Bill & Melinda Gates Foundation has made a $10 million program-related investment in the company to support the development and commercialization of safer and more effective vaccines and therapeutics. This follows recent announcements of the first Liquidia clinical trial of its lead seasonal flu candidate (LIQ001) and a collaborative agreement with the PATH Malaria Vaccine Initiative.

5 Mar 2011

Researchers use qMRI to confirm effect of CS treatment in patients with OA

A group of Canadian researchers led by Prof. Jean-Pierre Pelletier, Head of the Osteoarthritis Research Unit at the University of Montreal Hospital Research Centre, published a clinical trial in which they confirm, for the first time using quantitative Magnetic Resonance Imaging, the disease modifying effects of chondroitin sulphate, a symptomatic slow acting drug for osteoarthritis.

5 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented today.

4 Mar 2011

Miracor completes PICSO System pilot study in patients with ACS

Miracor Medical Systems GmbH announced today the successful completion of the pilot study of its PICSO System, designed to improve acute coronary syndrome revascularization following primary percutaneous coronary intervention.

4 Mar 2011

President's bioethics commission names international panel to review whether U.S. rules protect clinical trial participants in U.S., abroad

"Prompted by concerns about an unethical U.S.-sponsored study in the 1940s," the Presidential Commission for the Study of Bioethical Issues on Tuesday announced the formation of an international panel "that will examine whether current rules adequately protect volunteers in global clinical trials," Science's "ScienceInsider" blog reports.

4 Mar 2011

Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011.

3 Mar 2011

VICC introduces nation's first personalized cancer decision support tool

Vanderbilt-Ingram Cancer Center has launched the nation's first personalized cancer decision support tool, "My Cancer Genome," to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients.

3 Mar 2011

Genetics and cancer research

The 20th century was dominated by breakthroughs in physics and chemistry, but the 21st century will belong to genetics and biotechnology. Cancer research is just one area among many that is being transformed by the sequencing of the human genome. This was one of the topics discussed in our recent panel with leading cancer researchers, part of our Breakthroughs: Cancer series.

3 Mar 2011

Clinical trials in Australia take too long– need uniform standards: Report

A government report says that clinical trials for new medicines are taking too long and should be sped up so patients can access urgently needed treatment. The states and territories have been urged to adopt uniform rules on approving trials so the scientific experiments can be conducted more efficiently and effectively.

3 Mar 2011

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

Clinical Trial News and Research

Physical therapy within 24 hours of knee arthroplasty can improve recovery, cut hospital stays

Scientists identify regulatory T cells responsible for limiting immune response

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

FDA approves change to prescribing information for Gilead Sciences' Letairis

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Gates Foundation makes $10M PRI in Liquidia to support development of vaccines, therapeutics

Researchers use qMRI to confirm effect of CS treatment in patients with OA

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Nevirapine reduces HIV transmission risk from mother to breastfeeding infants by 75%

Miracor completes PICSO System pilot study in patients with ACS

President's bioethics commission names international panel to review whether U.S. rules protect clinical trial participants in U.S., abroad

Talecris granted EU orphan drug designation for Plasmin (human) to treat acute peripheral arterial occlusion

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

VICC introduces nation's first personalized cancer decision support tool

Genetics and cancer research

Clinical trials in Australia take too long– need uniform standards: Report

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer